PMV Pharmaceuticals, Inc. announced the pricing of initial public offering of 11.765 million common shares at $18.00 per share, at high end of expected range.
The company originally filed to sell 7.35 million common shares with an expected price of between $16.00 and $18.00 per share.
Earlier...
Prelude Therapeutics Inc (PRLD) announced that it has priced initial public offering of 8.325 million shares at $19 per share, the high end of expected range of between $17.00 and $19.00 per share. All of the shares of common stock are being offered by Prelude Therapeutics.
In addition, Prelude Therapeutics...
Graybug Vision, Inc. (GRAY) announced the pricing of its upsized initial public offering of 5.625 million shares of common stock at $16.00 per share. The offering is expected to close on September 29, 2020.
In addition, Graybug has granted underwriters a 30-day option to buy additional 843,750 shares...
The end of the third quarter is fast approaching. The third quarter IPO activity in the U.S. pharma/biotech sector has had a strong showing, with 30 listings so far for the period.
GoodRx Holdings Inc., which operates a digital platform for consumer healthcare products and services, announced the pricing of initial public offering of 34.6 million shares of Class A common stock at $33.00 per share, above the expected range of $24.00 and $28.00 per share. The offering is expected...
Santa Monica-based GoodRx Holdings, which operates a digital platform for consumer healthcare products and services, is scheduled to make its debut on the Nasdaq Global Select Market under the symbol "GDRX" on September 23, 2020.
Dallas, Texas-based Taysha Gene Therapies is scheduled to make its debut on the Nasdaq Global Select Market under the symbol "TSHA" on September 24, 2020.
Taysha Gene Therapies is a patient-centric gene therapy company developing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system.
COMPASS Pathways plc announced the pricing of upsized initial public offering of 7.5 million American Depositary Shares or ADSs, representing 7.5 million ordinary shares at $17 per ADS for total gross proceeds of $127.5 million.
COMPASS Pathways has filed to sell 6.7 million ADSs in the offering...
In the healthcare sector, two companies made their stock market debut in the first half of this month.
San Diego, California-based Metacrine is scheduled to go public on the Nasdaq Global Select Market under the symbol "MTCR" on September 16, 2020.
Knaus Tabbert AG said it aims to list the company's shares in the Prime Standard on the Frankfurt Stock Exchange. The offering will include existing shares from the holdings of the current shareholders HTP Investments 1 BV, Catalina Capital Partners B.V. and Palatium Beteiligungsgesellschaft mbH as well...